Sign In
Buy PHAT
$8.23
-0.220 (-2.60%)
At Close: Aug 05, 2026
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
08:00am, Monday, 06'th Oct 2025
Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational excellence Appointment strengthens Phathom'
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's Why
01:01pm, Thursday, 18'th Sep 2025
Phathom Pharmaceuticals (PHAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?
06:06pm, Monday, 08'th Sep 2025
The mean of analysts' price targets for Phathom Pharmaceuticals (PHAT) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreemen
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
07:59am, Monday, 25'th Aug 2025
FLORHAM PARK, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet
10:55am, Friday, 22'nd Aug 2025
The consensus price target hints at an 87.2% upside potential for Phathom Pharmaceuticals (PHAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e
Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing
08:00am, Wednesday, 20'th Aug 2025
FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed l
Phathom Pharmaceuticals, Inc. (PHAT) Q2 2025 Earnings Call Transcript
10:51pm, Thursday, 07'th Aug 2025
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Eric Sciorilli - Corporate Participant Robert Breedlove - VP of Finance & P
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
09:11am, Thursday, 07'th Aug 2025
Phathom Pharmaceuticals, Inc. (PHAT) came out with a quarterly loss of $0.79 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to a loss of $1.25 per share a year ago.
Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
06:59am, Thursday, 07'th Aug 2025
FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
08:00am, Monday, 28'th Jul 2025
FLORHAM PARK, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism
04:54am, Wednesday, 25'th Jun 2025
VOQUEZNA's FDA exclusivity through 2032 and superior efficacy in GERD and H. pylori create a strong competitive moat in a $3.2B+ market. Rapid commercial uptake, robust DTC marketing, and >80% insuran
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Monday, 23'rd Jun 2025
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
07:59am, Monday, 23'rd Jun 2025
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
FLORHAM PARK, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy
10:08am, Tuesday, 10'th Jun 2025
I'm bullish on Phathom Pharmaceuticals, Inc. after the FDA granted 10-year exclusivity to their flagship GI drug, Voquezna, giving them near-monopoly status. For those who don't know, this is a big de
